Protective effects of the immunopotentiator from Pantoea agglomerans 1 on chemotherapeutic agent-induced macrophage growth inhibition

Anticancer Research

Volumn 30, Issue 6, 2010, Pages 2033-2040

  Hebishima, Takehisa ^a,b,c   Matsumoto, Yasunobu ^c   Watanabe, Gen ^a,b   Soma, Gen Ichiro ^d,e   Kohchi, Chie ^d,e   Taya, Kazuyoshi ^a,b   Hayashi, Yoshihiro ^c   Hirota, Yoshikazu ^a,b  

^a TOKYO UNIVERSITY OF AGRICULTURE AND TECHNOLOGY   (Japan)

^b GIFU UNIVERSITY   (Japan)

^c UNIVERSITY OF TOKYO   (Japan)

^d TOKUSHIMA BUNRI UNIVERSITY   (Japan)

^e KAGAWA UNIVERSITY   (Japan)

Author keywords

Apoptosis; Chemotherapy; Immunomodulator; IP PA1; Macrophage

Indexed keywords

BACTERIUM LIPOPOLYSACCHARIDE; DOXORUBICIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LIPOCORTIN 5; NITRIC OXIDE; PANTOEA AGGLOMERANS 1; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL CELL; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL GROWTH; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GROWTH INHIBITION; HUMAN; HUMAN CELL; IMMUNOPOTENTIATION; IMMUNOSTIMULATION; MACROPHAGE; MACROPHAGE ACTIVATION; MOUSE; NITROBLUE TETRAZOLIUM TEST; NONHUMAN; PRIORITY JOURNAL; WESTERN BLOTTING;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BCL-X PROTEIN; CELL LINE; CELL PROLIFERATION; MACROPHAGES; MICE; NF-KAPPA B; PANTOEA; PROTO-ONCOGENE PROTEINS C-BCL-2;

EID: 77955066606     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Momparler RL, Karon M, Siegel SE and Avila F: Effect of Adriamycin on DNA, RNA, and protein synthesis in cell-free systems and intact cells. Cancer Res 36: 2891-2895, 1976.
2. Rosenberg B, Vancamp L, Trosko JE and Mansour VH: Platinum compounds: a new class of potent antitumor agents. Nature 222: 385-386, 1969.
3. Heidelberger C, Chaudhuri NK, Danneberg P, Mooren D, Griesbach L, Duschinsky R, Schnitzer RJ, Pleven E and Scheiner J: Fluorinated pyrimidens, a new class of tumour-inhibitory compounds. Nature 179: 663-666, 1957.
4. Farber S and Diamond LK: Temporary remissions in acute leukemia in children produced by folic acid antagonist, 4-aminopteroyl-glutamic acid. N Engl J Med 238: 787-793, 1948.
5. Thompson CB: Apoptosis in the pathogenesis and treatment of disease. Science 267: 1456-1462, 1995.
6. Hickman JA, Potten CS, Merritt AJ and Fisher TC: Apoptosis and cancer chemotherapy. Philos Trans R Soc Lond B Biol Sci 345: 319-325, 1994.
7. Zitvogel L, Apetoh L, Ghiringhelli F and Kroemer G: Immunological aspects of cancer chemotherapy. Nat Rev Immunol 8: 59-73, 2008.
8. Utsugi T, Schroit AJ, Connor J, Bucana CD and Fidler IJ: Elevated expression of phosphatidylserine in the outer membrane leaflet of human tumor cells and recognition by activated human blood monocytes. Cancer Res 51: 3062-3066, 1991.
9. Takano R, Nose M, Kanno H, Nishihira T, Hiraizumi S, Kobata A and Kyogoku M: Recognition of N-glycosidic carbohydrates on esophageal carcinoma cells by macrophages cell line THP-1. Am J Pathol 137: 393-401, 1990.
10. Savill J, Fadok V, Henson P and Haslett C: Phagocyte recognition of cells undergoing apoptosis. Immunol Today 14: 131-136, 1993.
11. Taniyama T and Holden HT: Requirement of histocompatible macrophages for the induction of a secondary cytotoxic response to syngeneic tumor cells in vitro. J Immumol 125: 43-49, 1979.
12. Voll RE, Herrmann M, Roth EA, Stach C and Kalden JR: Immunosuppressive effects of apoptotic cells. Nature 390: 350-351, 1997.
13. Dominguez-Rodriguez JR, Chaparro-Huerta V, Hernandez-Flores G, Gomez-Contreras PC, Lerma-Diaz JM, Ortiz-Lazareno PC, Cervantes-Munguia R, Orbach-Arbouys S, Scott-Algara D and Cuellar AB: In vivo adriamycin-induced apoptosis in peritoneal murine macrophages: partial participation of a caspase cascade. Anticancer Res 24: 2689-2696, 2004.
14. Inagawa H, Nishizawa T, Tsukioka D, Suda T, Chiba Y, Okutomi T, Morikawa A, Soma G and Mizuno D: Homeostasis as regulated by activated macrophage. II. LPS of plant origin other than wheat flour and their concomitant bacteria. Chem Pharm Bull 40: 994-997, 1992.
15. Inagawa H, Nishizawa T, Yoshioka N, Taniguchi Y, Kohchi C and Soma G: Preventive and therapeutic of lipopolysaccharide derived from edible Gram-negative bacteria to various diseases. Curr Drug Therapy 2: 26-32, 2008.
16. Nishizawa T, Inagawa H, Oshima H, Okutomi T, Tsukioka D, Iguchi M, Soma G and Mizuno D: Homeostasis as regulated by activated macrophage. I. Lipopolysaccharide (LPS) from wheat flour: isolation, purification and some biological activities. Chem Pharm Bull 40: 479-483, 1992.
17. Kohchi C, Inagawa H, Nishizawa T, Yamaguchi T, Nagai S and Soma G: Applications of lipopolysaccharide derived from Pantoea agglomerans (IP-PA1) for health care based on macrophage network theory. J Biosci Bioeng 102: 485-496, 2006.
18. Hebishima T, Matsumoto Y, Soma G, Kohchi C, Watanabe G, Taya K, Hayashi Y and Hirota Y: Immune recovery effects of immunopotentiator from Pantoea agglomerans 1 (IP-PA1) on low antibody productions to Salmonella enteritidis vaccine and sheep red blood cells in dexamethasone-treated stressed chicken models. J Vet Med Sci, in press.
19. Catz SD and Johnson JL: Transcriptional regulation of bcl-2 by nuclear factor κB and its significance in prostate cancer. Oncogene 20: 7342-7351, 2001.
20. Lee HH, Dadgostar H, Cheng Q, Shu J and Cheng G: NF-κB-mediated up-regulation of Bcl-x and Bfl-1/A1 is required for CD40 survival signaling in B lymphocytes. Proc Natl Acad Sci 96: 9136-9141, 1999.
21. Scheid MP, Lauener RW and Duronio V: Role of phosphatidylinositol 3-OH-kinase activity in the inhibition of apoptosis in haemopietic cells: phosphatidylinositol 3-OH-kinase inhibitors reveal a difference in signaling between interleukin-3 and granulocyte-macrophage colony stimulating factor. Biochem J 321: 159-162, 1995.
22. Haeffner A, Déas O, Mollereau B, Estaquier J, Mignon A, Haeffner-Cavaillon N, Charpentier B, Senik A and Hirsch F: Growth hormone prevents human monocytic cells from Fas-mediated apoptosis by up-regulating Bcl-2 expression. Eur J Immunol 20: 334-344, 1999.
23. Akira S and Takeda K: Toll-like receptor signaling. Nat Rev Immunol 4: 499-511, 2004.
24. Taniguchi Y, Nishizawa T, Honda T, Yoshioka N, Inagawa H, Kohchi C and Soma G: Development and potential use of a monoclonal antibody to the lipopolysaccharide of Pantoea agglomerans (IP-PA1). Anticancer Res 27: 3701-3706, 2007.
25. Enari M, Talanian RV, Wong WW and Nagata S: Sequential activation of ICE-like and CPP32-like proteases during Fas-mediated apoptosis. Nature 380: 723-726, 1996.
26. Fadok VA, Voelker DR, Campbell PA, Cohen JJ, Bratton DL and Henson PM: Exposure of phosphatidylserine on the surface of apoptotic lymphocytes treggers specific recognition and removal by macrophages. J Immunol 148: 2207-2216, 1992.
27. Oltvai ZN, Milliman CL and Korsmeyer SJ: Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell 74: 609-619, 1993.
28. Hockenbery D, Nunez G, Milliman C, Schreiber RD and Korsmeyer SJ: Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature 348: 334-336, 1990.
29. Boise LH, González-Gracia M, Postema CE, Ding L, Lindsten T, Turka LA, Mao X, Nuñez G and Thompson CB: bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death. Cell 74: 597-608, 1993.
30. Traeckner EB-M, Pahl HL, Henkel T, Schmidt KN, Wilk S and Baeuerle PA: Phosphorylation of human IκB-α on serines 32 and 36 controls IκB-α proteolysis and NF-κB activation in response to diverse stimuli. EMBO J 14: 2876-2883, 1995.
31. Sen R and Baltimore D: Multiple nuclear factor interact with the immunoglobulin enhancer sequences. Cell 46: 705-716, 1986.
32. Xie Q, Kashiwabara Y and Nathan C: Role of transctription factor NF-κB/Rel in induction of nitric oxide synthase. J Biol Chem 269: 4705-5708, 1994.
33. Shakhov AN, Collart MA, Vassalli P, Nedospasov SA and Jongeneel CV: κB-type enhancers are involved in lipopolysaccharide-mediated transcriptional activation of the tumor necrosis factor α gene in primary macrophages. J Exp Med 171: 35-47, 1990.
34. Lesmeister MJ, Jorgenson RL, Young SL and Misfeldt ML: 17β-Estradiol suppresses TLR3-induced cytokine and chemokine production in endometrial epithelial cells. Reprod Biol Endocrinol 3: 74-88, 2005.
35. He W, Liu Q, Wang L, Chen W, Li N and Cao X: TLR4 signaling promotes escape of human lung cancer cells by inducing immunosuppressive cytokines and apoptosis resistance. Mol Immunol 44: 2850-2859, 2007.
36. Taniguchi Y, Yoshioka N, Nishizawa T, Inagawa H, Kohchi C and Soma G: Utility and safety of LPS-based fermented flour extract as a macrophage activator. Anticancer Res 29: 859-864, 2009.
37. Drapier JC and Hibbs JB: Differentiation of murine macrophages to express nonspecific cytotoxicity for tumor cells results in L-arginine-dependent inhibition of mitochondrial iron-sulfur enzymes in the macrophage effector cells. J Immunol 140: 2829-2838, 1988.
38. Decker T, Lohmann-Matthes ML and Gifford GE: Cell-associated tumor necrosis factor (TNF) as a killing mechanism of activated cytotoxic macrophages. J Immunol 158: 957-962, 1987.
39. Hino M, Kohchi C, Nishizawa T, Yoshida A, Nakata K, Inagawa H, Hori H, Makino K, Terada H and Soma G: Innate-immune therapy for lung carcinoma based on tissue-macrophage activation with lipopolysaccharide. Anticancer Res 25: 3747-3754, 2005.